Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

43.58
-3.4100-7.26%
Post-market: 43.920.3425+0.79%19:57 EDT
Volume:2.92M
Turnover:130.68M
Market Cap:1.49B
PE:-6.74
High:47.13
Open:47.09
Low:43.51
Close:46.99
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:1.10
T/O Rate:10.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.65
PE(LYR):-4.48

Loading ...

Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery

Simply Wall St.
·
May 13

Nektar price target lowered to $80 from $95 at Wedbush

TIPRANKS
·
May 12

Stock Track | Nektar Therapeutics Plummets 5.13% Intraday After Wedbush Cuts Price Target

Stock Track
·
May 11

Nektar Therapeutics Is Maintained at Neutral by Wedbush

Dow Jones
·
May 11

Nektar Therapeutics : Wedbush Cuts Target Price to $80 From $95

THOMSON REUTERS
·
May 11

Nektar Therapeutics Charts Aggressive Path With REZPEG

TIPRANKS
·
May 09

Nektar Therapeutics Establishes New Equity Distribution Agreement

TIPRANKS
·
May 09

Nektar Therapeutics Names Rubinstein New Interim CFO

Dow Jones
·
May 09

BRIEF-Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC Filing

Reuters
·
May 09

Nektar Therapeutics - to Offer up to $150 Mln in Common Stock via Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
May 09

Nektar Therapeutics - Sandra Gardiner to Retire as Interim CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 09

Nektar enters equity distribution deal for up to $150 million at-the-market offering

Reuters
·
May 09

Nektar Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Nektar price target raised to $192 from $105 at Piper Sandler

TIPRANKS
·
May 08

Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating

TIPRANKS
·
May 08

Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

TIPRANKS
·
May 08

Nektar Therapeutics Q1 net loss narrows on lower G&A costs

Reuters
·
May 08

Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate

Benzinga Earnings
·
May 08

BRIEF-Nektar Therapeutics Q1 EPS USD -1.82

Reuters
·
May 08

Nektar Therapeutics Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 08